key: cord-0976757-53c8e10y authors: Karhadkar, Tejas R.; Pilling, Darrell; Gomer, Richard H. title: Serum Amyloid P inhibits single stranded RNA-induced lung inflammation, lung damage, and cytokine storm in mice date: 2020-08-27 journal: bioRxiv DOI: 10.1101/2020.08.26.269183 sha: 9d30beb093cada2e3637ea0a7543b133eecbae4c doc_id: 976757 cord_uid: 53c8e10y SARS-CoV-2 is a single stranded RNA (ssRNA) virus and contains GU-rich sequences distributed abundantly in the genome. In COVID-19, the infection and immune hyperactivation causes accumulation of inflammatory immune cells, blood clots, and protein aggregates in lung fluid, increased lung alveolar wall thickness, and upregulation of serum cytokine levels. A serum protein called serum amyloid P (SAP) has a calming effect on the innate immune system and shows efficacy as a therapeutic for fibrosis in animal models and clinical trials. In this report, we show that aspiration of the GU-rich ssRNA oligonucleotide ORN06 into mouse lungs induces all of the above COVID-19-like symptoms. Men tend to have more severe COVID-19 symptoms than women, and in the aspirated ORN06 model, male mice tended to have more severe symptoms than female mice. Intraperitoneal injections of SAP starting from day 1 post ORN06 aspiration attenuated the ORN06-induced increase in the number of inflammatory cells and formation of clot-like aggregates in the mouse lung fluid, reduced ORN06-increased alveolar wall thickness and accumulation of exudates in the alveolar airspace, and attenuated an ORN06-induced upregulation of the inflammatory cytokines IL-1β, IL-6, IL-12p70, IL-23, and IL-27 in serum. Together, these results suggest that aspiration of ORN06 is a simple model for both COVID-19 as well as cytokine storm in general, and that SAP is a potential therapeutic for diseases with COVID-19-like symptoms as well as diseases that generate a cytokine storm. Coronavirus disease 2019 (COVID-19) is generally caused by inhalation of the severe acute respiratory syndrome coronavirus 2 (SARS CoV 2), a single-stranded RNA (ssRNA) virus related to severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome-related coronavirus (MERS-CoV) (1) . Human patients and murine models of SARS-CoV, MERS, and SARS-CoV2 indicate that severe disease may be triggered by a cytokine storm, in which, as in other cytokine storm associated diseases, an over exuberant production of cytokines leads to the accumulation of immune cells in sensitive organs such as the lungs (2, 3) . Although there are similar numbers of confirmed SARS-CoV2 cases between men and women, severe COVID-19 disease, as measured by hospitalization, admission to intensive care units, and rates of mortality, are 1.5 to 2 times higher in men than women (4) (5) (6) (7) . These data are independent of other known factors, such as smoking, diabetes, obesity, heart disease, chronic kidney disease, or chronic lung disease (7, 8) . Lung biopsy and autopsy findings indicate that COVID-19 is associated with an accumulation of cell-free protein-rich exudate in the alveoli, alveolar wall thickening, and inflammation (accumulation of immune cells) (9) (10) (11) (12) (13) (14) (15) . COVID-19 patients are also at risk of disseminated intravascular coagulation and deposition of fibrin clots in the lungs (9, 10, 14-16). In both animal models and COVID-19 patients, there is a consistent accumulation of macrophages in the lungs, whereas increased numbers of lung neutrophils appear to be associated with comorbidities such as pneumonia (14, 17, 18). Serum amyloid P (SAP; PTX2) is a member of the pentraxin family of proteins that includes C-reactive protein (CRP; PTX1) and pentraxin-3 (PTX3). SAP is made by hepatocytes and secreted into the blood (19, 20) . SAP binds to a variety of molecules including DNA and apoptotic debris, bacterial polysaccharides, amyloid deposits, and bacterial and viral proteins (21-23). Phagocytic cells such as monocytes and macrophages then bind the SAP and engulf the debris or other material the pentraxin has bound (24). SAP binds to Fc receptors (receptors for IgG) as well as the C-type lectin receptor DC-SIGN/CD209 on monocytes and macrophages (24-28), and inhibits the formation of pro-inflammatory and pro-fibrotic macrophages, and promotes the formation of immuno-regulatory macrophages (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) . In addition to promoting the formation of immuno-regulatory macrophages, SAP induces macrophages to secrete the antiinflammatory cytokine IL-10 (34, 35, 41) . SAP decreases neutrophil binding to extracellular matrix components (42) (43) (44) , and in a mouse model of lung inflammation, SAP injections starting 24 hours after insult reduced the number of neutrophils in the lungs (44) . In animal models and human clinical trials, SAP inhibits fibrosis (30, 35, [45] [46] [47] . SAP is also effective as an inhibitor of influenza A virus infections (48) (49) (50) . Cells can sense the presence of the SARS CoV 2 ssRNA virus using the ssRNAsensitive intracellular toll-like receptors TLR7 and TLR8 (51, 52) . Adding GU-rich ssRNAs to human peripheral blood immune cells induces proinflammatory cytokine production, and tail vein injections of GU-rich ssRNAs in mice lead to pulmonary edema, accumulation of inflammatory cells, and alveolar hemorrhage/damage in the lung (51, 53) . In this report, we show that oropharyngeal aspiration of ORN06 induces a cytokine storm and lung damage in mice with remarkable similarities to the cytokine storm and lung damage seen in COVID-19 patients, including more severe effects in male mice than female mice. We find that SAP strongly attenuates the ORN06 effects, suggesting that SAP could be a potential therapeutic for severe COVID-19 and possibly cytokine storms in general. Purified human SAP (30C-CP1104LY) was purchased from Fitzgerald Industries (Acton, MA). Before use, the SAP was buffer exchanged into 20 mM sodium phosphate, pH 7.4 to remove sodium azide and EDTA present in the commercial preparation. The SAP was diluted 1:1 with 20 mM sodium phosphate, pH 7.4, and added to Amicon Ultra 0.5ML 10 kDa cutoff centrifugal filter units (Millipore-Sigma, Burlington, MA) and centrifuged at 10,000 x g for 10 minutes. The SAP in the upper reservoir was then resuspended with 0.4 ml 20 mM phosphate buffer and centrifuged again. This process was repeated four times to exchange the buffer to 20 mM sodium phosphate. Buffer-exchanged preparations were then checked for protein concentration by OD 260/280/320 using a Take3 micro-volume plate with a SynergyMX plate reader (BioTek, Winooski, VT, USA) as previously described (54) . The SAP, at 2.5-4 mg/ ml, was stored in aliquots at 4 ºC and used within 14 days. SDS-PAGE of 1 µg of this SAP showed a single band at the expected molecular mass of 26 kDa. 5-week old 20 g male and female C57BL/6 mice (Jackson Laboratories, Bar Harbor, ME) were given an oropharyngeal aspiration of 1 mg/kg (or less where indicated) ORN06/LyoVec (a ssRNA oligonucleotide with 6 UGU repeats complexed with a lipid which protects the ssRNA from degradation; henceforth referred to as ORN06) (InvivoGen, San Diego, CA) in 50 µl phosphate-buffered saline (PBS), or an oropharyngeal aspiration of an equal volume of PBS as a control, following (55, 56) . At 24 and 48 hours after ORN06 insult, the control mice and some of the ORN06-treated mice were given intraperitoneal injections of 100 µl PBS, or SAP diluted to a dose of 2.5 mg/kg in 100 µl PBS. At day 3, mice were euthanized by CO 2 inhalation, and bronchoalveolar lavage fluid (BALF) was obtained as previously described (55, 57) . The experiment was performed in accordance with the recommendations in the Guide for the Care and use of Laboratory Animals of the National Institutes of Health. The Texas A&M University Animal Use and Care Committee approved the protocol. BALF cells were counted and processed to prepare cell spots as described previously (58, 59) . After air drying for 48 hours at room temperature, some of the prepared BALF cell spots were fixed and treated with Wright-Giemsa stain (Polysciences, Inc., Warrington, PA) following the manufacturer's instructions. At least 150 cells per mouse were examined and quantified for cell type following the manufacturer's instructions using a CME microscope (Leica, Buffalo Grove, IL) with a 40x objective, and selected areas were imaged with a 100x oil immersion objective on an Eclipse Ti2 microscope (Nikon, Melville, NY) with a 10 megapixel color CCD camera (Amscope, Irvine, CA). Immunochemistry on BALF cell spots and counts of cells was performed as described previously (57, 60, 61) . Slides were incubated with monoclonal antibodies overnight at 4 o C using anti-CD3 (100202, clone 17A2, BioLegend, San Diego, CA) to detect T-cells, anti-CD11b After collecting BALF, the lungs from the mice were harvested and inflated with Surgipath frozen section compound (#3801480, Leica, Buffalo Grove, IL), frozen on dry ice, and stored at -80 ºC. 10 µm cryosections of lungs were placed on Superfrost Plus glass slides (VWR) and were air dried for 48 hours. The slides were fixed in acetone for 20 minutes, and then air dried. Slides were incubated for 5 minutes in water at room temperature and then stained for two minutes at room temperature with Gill's hematoxylin No. 3 solution (Sigma-Aldrich, St. Louis, MO) diluted 1:3 with water and then rinsed under tap water for 1 minute at room temperature. The slides were then incubated with 0.1% eosin for 1 minute and then washed by dipping in water for 10 seconds. The stained slides were allowed to air dry for 2 hours; cleared with xylenes (VWR); and mounted with Permount mounting medium (Electron Microscopy Sciences). After drying the mounted slides for 48 hours, images were captured using a 40x objective on a Nikon Eclipse Ti2 microscope. Images of a 10 µm divisions calibration slide (#MA663, Swift Microscope World, Carlsbad, CA) were used for size bars. Three fields of view were chosen randomly for imaging. Image quantification was done using Image J (NIH, Bethesda, MD). Using the Set Scale function from Image J on a 1 mm scale bar image, all the images were calibrated to the same scale by applying the settings globally. Using the 'Straight' command, the length of the alveolar wall on the image was measured and was recorded with the 'Measure' command. Eight measurements of the alveolar wall thickness were recorded for each image. To assess exudates in the alveoli, for each mouse, for the stained cryosections described above, three randomly chosen fields of view were photographed with a 20x objective, and both the number of exudate-containing alveoli and exudate-free alveoli in each image were counted. The percent of exudate-containing alveoli was then calculated. Using the Threshold function and the Measure Tool in NIH ImageJ, the percent area of each 20x objective image of lung cryosections described above containing tissue (not counting pale pink exudates) was measured, and this percentage was subtracted from 100% to obtain the percent area of the image occupied by the alveolar airspace. The threshold was then adjusted to obtain the percent area of the image occupied by tissue and exudate. The percent area of the image occupied by exudate was then calculated by subtracting the percent area of the image occupied by tissue from the percent area After mice were euthanized, blood was collected from the abdominal aorta and chilled on ice. After 30 minutes, the blood was clarified by centrifugation at 10,000 × g for 5 minutes at 4 °C to isolate serum, which was then stored at -80 °C (62-64). Sera were assayed for cytokines using a 13-plex LEGENDplex Mouse Inflammation Panel kit (Biolegend, San Diego, CA) following the manufacturer's instructions using an Accuri C6 flow cytometer (BD Bioscience, Franklin Lakes, NJ). Statistical analyses with t tests or 1-way ANOVA with the indicated post-test were done using GraphPad Prism 7 (GraphPad, San Diego, CA). Significance was defined as p < 0.05. To determine if aspiration of ORN06 can induce lung inflammation and damage, and whether SAP injections might affect this, mice were treated with an oropharyngeal aspiration of mice, compared to control, ORN06 increased the number of monocyte/macrophages, and SAP treatments reversed these ORN06-induced increases (Fig 1B and S1 Fig) . Similar results were observed for lymphocytes, with the exception that control males had more BALF lymphocytes that control females, and the ORN06 treated males showed a wide range of BALF lymphocyte counts and this was thus not statistically different from control (Fig 1C and S1 Fig) . The ORN06 treatment did not significantly increase the number of neutrophils in the BALF from male or female mice (Fig 1D and S1 Fig) . Compared to ORN06 alone, SAP injections in ORN06-treated mice increased body weight at day 3, with a significant effect in female but not male mice (S2 Immunohistochemistry on BALF cell spots indicated that compared to control, ORN06 increased the number of CD11c-positive macrophages and/or dendritic cells, and increased the number of CD45-positive leukocytes for both male and female mice, and these effects were reversed with SAP injections (Fig 2 and S4 Fig) After BAL, lungs were inflated and cryosections were immunostained to determine if ORN06 aspiration affects the local density of selected immune cells. Compared to control, ORN06 increased the density of CD11b positive blood and inflammatory macrophages and CD45 positive leukocytes, and SAP reversed this, for male and female mice (Fig 3, S5 Fig, and CD11c positive alveolar macrophages and dendritic cells, and SAP reversed this, with significant effects for female but not male mice (Fig 3 and S6 Fig). ORN06 with or without SAP had no significant effect for male or female mice on the local density of Mac2/Gal3 positive alveolar macrophages (65) or Ly6G positive neutrophils (Fig 3 and S6 Fig) . We noticed that the ORN06 treatment with subsequent buffer injections caused the formation of irregular clot-like aggregates visible as dark blue irregular objects in the Wright-Giemsa-stained BALF from 2 of 3 male mice (Fig 4) . Defining a clot-like aggregate as an irregularly shaped 2-10 µm object in the BALF staining dark blue with Wright-Giemsa stain, no clot-like aggregates were observed in the BALF cell spots from the 3 male and 5 female control mice or the 3 male and 3 female ORN06-treated with subsequent SAP injections mice. These results indicate that SAP injections may inhibit the formation of clot-like aggregates in the lungs. Compared to the control group, for male and female mice, ORN06 aspirated and bufferinjected mice showed an increase in alveolar wall thickness, and this was reduced by treatment with SAP (Fig 5 A-D and S7 Fig). ORN06 treatment with or without SAP caused a larger increase on alveolar wall thickness in female compared to male mice (S7 Fig). We also noticed that for male and female mice, ORN06 caused the formation of exudates visible as light pink objects in the interior of alveoli (the alveolar airspace) in cryosections stained with hematoxylin & eosin (red arrow, Fig 5B, Fig 5 E and F, and S7 Fig) . This effect was reversed by SAP injections (Fig 5A-C, E, and F, and S7 Fig). Compared to female mice, male mice had a greater percentage of alveoli containing ORN06-induced exudates (S7 Fig). Together, these results indicate that ORN06 inhalation increases alveolar wall thickness and the formation of exudates in alveoli, and that SAP injections can inhibit both of these ORN06-induced effects. Compared to control, ORN06 treatment of mice caused serum concentrations of IL-1β, IL-6, IL-12p70, IL-23, and IL-27 to increase at day 3, and SAP injections decreased all of these ORN06-induced increases (Fig 6 A-E) . Male mice had a somewhat greater ORN06-induced increase in IL-6 than female mice, but did not show an ORN06-induced increase in IL-23 (S8 (S9 and S10 Fig) . Together, these results suggest that ORN06 inhalation increases some serum cytokines in mice, and that SAP injections can inhibit these ORN06-induced effects. In this report, we observed that aspiration of ORN06 induced the accumulation of immune cells, alveolar wall thickening, and presence of lung exudates, as previously described when mice were treated with GU-rich ssRNA by tail vein injection (51) . Aspiration of ORN06 also led to the formation of clot-like aggregates in some male mouse lung fluids. ORN06 aspiration increased levels of CD11b+, CD11c+, and CD45+ macrophages, CD3-lymphocytes, but not Ly6G positive neutrophils in the lungs, and upregulated IL-1β, IL-6, IL-12p70, IL-23, and IL-27 in the serum. We also observed differences in the response to ORN06 between male and female mice. Unlike tail vein injection, aspiration of the GU-rich ssRNA did not induce death of the mice over 72 hours (51) . In mice treated with aspirated ORN06, injections of SAP attenuated lung inflammation, alveolar wall thickening, the presence of lung exudates and clotlike aggregates, and elevated serum cytokines induced by ORN06 aspiration. These results suggest that ORN06 aspiration mimics some of the characteristics of COVID-19, and that SAP could be a potential therapeutic for severe COVID-19 disease and other conditions where a cytokine storm is a clinical problem. Compared to both healthy controls and patients with viral or bacterial pneumonia, COVID-19 patients, especially severe cases, have in their peripheral blood reduced numbers of CD14+CD16-DR+ "classical" monocytes, which may be due to the increased levels of IL-6 and/or dysregulated myelopoiesis (1, (66) (67) (68) (69) (70) (71) . In the BAL, patients with severe COVID-19 have more macrophages than mild cases or healthy controls, and the increased macrophage numbers appear to be due to the presence of recruited monocyte-derived inflammatory macrophages (17, [72] [73] [74] . We found that ORN06-induced increases in BALF cell counts were mirrored by an increase in CD11c+ and CD45+ cells with the morphology of macrophages, suggesting that ORN06 stimulates the accumulation of CD11c+CD45+ alveolar macrophages, but whether this is due to the proliferation of resident alveolar macrophages, migration of CD11c+CD45+ interstitial macrophages into the alveoli, or a rapid phenotypic conversion of recruited CD11b+CD11c-to CD11b-CD11c+ macrophages is unknown (75, 76) . Aspiration of ORN06 led to increased numbers of CD11b+, CD11c+, and CD45+ cells, but not Mac2/Gal3 positive cells, retained in the lungs after BAL. As Mac2/Gal3 is a marker for tissue resident lung macrophages (65) , these data suggest that ORN06 generates a response that induces the recruitment of CD11b+CD45+ inflammatory macrophages, which may undergo phenotypic conversion to CD11b-CD11c+CD45+ macrophages, and/or ORN06 induces the proliferation of lung resident CD11c+CD45+ interstitial macrophages (75-77). Injections of SAP attenuated the accumulation of macrophages in both the BAL fluid and in the post-BAL lung tissue. These data suggest that SAP can be used to target the recruited macrophage populations without altering the tissue resident macrophages, or elevating the neutrophils in the lung. ORN06 aspiration also led to a small but significant increase in the number of BALF lymphocytes, which were CD3 negative, suggesting this was due to either the recruitment of CD3 negative natural killer (NK) cells or other types of innate lymphoid cells (ILC), or the proliferation of lung resident ILCs (78) (79) (80) . SAP was also effective at attenuating the ORN06induced increase in BALF lymphocytes. COVID-19 patients have reduced numbers of ILC, including NK cells, in the peripheral blood, but scRNA-seq analysis from COVID-19 patients indicate higher numbers of NK cells in the BAL (70) . NK cells and other ILCs are potent producers of a variety of cytokines, depending on the subtype of ILCs, stimulus, and tissue where the ILCs are found, but how the changes in the number and composition of ILCs subsets affect cytokine levels in COVID-19 is still unclear (1, 81) . COVID-19 is also characterized by a "cytokine storm" with increased levels of proinflammatory cytokines in the blood, such as IL-1β, TNF-α, IL-6, IL-12 (67, 70, 71, 82) , and we detected increased IL-1β, IL-6, IL-12, IL-23, and IL-27 in the serum following ORN06 aspiration. Injections of SAP attenuated the increased levels of the above cytokines, suggesting that SAP can either induce cells to degrade extracellular cytokines, or inhibit cells from secreting cytokines the above cytokines. SAP also elevated the serum levels of the "anti-inflammatory cytokine" IL-10, as observed previously (27, 35, 41) . Previous studies suggest that IL-17A plays an important role in enhancing antiviral T helper type 1 responses in the female genital tract, where female mice lacking IL-17A have lower proportions of IFN-γ+ T h 1 cells than wild type female mice (83) . Compared to male mice, female mouse bladders have higher IL-17 expression (84) .We observed that ORN06 decreased serum IL-17A in female but not male mice, and that SAP reversed the ORN06 effect in female mice. Together, this suggests that SAP can reverse the effects of ORN06 on several serum cytokines. Severe COVID-19 disease is 1.5 to 2 times higher in men than women (4) (5) (6) (7) (8) .We found that ORN06 aspiration led to a higher BALF cell numbers, clot-like aggregates, and alveoli containing exudates in male mice compared to female mice, which suggests a similar response in mice compared to humans. Many diseases are associated with sex-based differences in disease incidence, prevalence, and severity (85) (86) (87) , but the causes of these differences for COVID-19 in particular remain unclear. Together, our results and the work described above suggest the intriguing possibility that aspiration of oligonucleotides such as ORN06 could be a simple model for COVID-19 infection. In addition, SAP strongly attenuated the effects of aspiration of ORN06, suggesting that SAP could be a potential therapeutic for severe COVID-19 disease and possibly other diseases where a cytokine storm is a contributing factor for disease severity or progression. females). ** p < 0.01 and **** p < 0.0001 (1-way ANOVA, Bonferroni's test). For A-D, there was no significant difference between the control group and the SAP-treated group. Cell spots of BALF at day 3 were stained for the indicated markers. The percentage of cells stained was determined in 5 randomly chosen fields of 100-150 cells, and the percentage was multiplied by the total number of BALF cells for that mouse to obtain the total number of BALF cells staining for the marker. Values are mean ± SEM, n = 6 mice (3 males and 3 females), except control group where n = 8 (3 males and 5 females). **** = p < 0.001 (1-way ANOVA, Dunnett's test). For A-E, there was no significant difference between the control group and the SAP-treated group. ORN06 and then buffer, and ORN06 and then SAP-treated mice. Values are mean ± SEM, n = 6 mice (3 males and 3 females). * p < 0.05 and ** p < 0.01 (t-test). # p < 0.05 (Welch's t-test). (1-way ANOVA, Bonferroni's test). Immunology of COVID-19: Current State of the Science The Immunology of Macrophage Activation Syndrome The genetics of macrophage activation syndrome Clinical Characteristics of Coronavirus Disease 2019 in China Impact of sex and gender on COVID-19 outcomes in Europe Biological sex impacts COVID-19 outcomes Considering how biological sex impacts immune responses and COVID-19 outcomes Aging, Male Sex, Obesity, and Metabolic Inflammation Create the Perfect Storm for COVID-19 Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet Respiratory Medicine Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer COVID-19 Autopsies Histopathologic Changes and SARS-CoV-2 Immunostaining in the Lung of a Patient With COVID-19 Autopsy Findings and Venous Thromboembolism in Patients With COVID-19 Pathological Findings of Postmortem Biopsies From Lung, Heart, and Liver of 7 Deceased COVID-19 Patients Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans Fc Receptor Engagement Mediates Differentiation of Cardiac Fibroblast Precursor Cells Serum Amyloid P Therapeutically Attenuates Murine Bleomycin-Induced Pulmonary Fibrosis via Its Effects on Macrophages Serum amyloid P ameliorates radiation-induced oral mucositis and fibrosis TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P Serum amyloid P inhibits fibrosis through Fc gamma R-dependent monocyte-macrophage regulation in vivo Serum amyloid P attenuates M2 macrophage activation and protects against fungal spore-induced allergic airway disease Identification of markers that distinguish monocyte-derived fibrocytes from monocytes, macrophages, and fibroblasts Monocyte differentiation and macrophage priming are regulated differentially by pentraxins and their ligands C-reactive protein (CRP) but not the related pentraxins serum amyloid P and PTX3 inhibits the proliferation and induces apoptosis of the leukemia cell line Mono Mac 6 Pentraxin-2 suppresses c-Jun/AP-1 signaling to inhibit progressive fibrotic disease Macrophage Differentiation and Polarization via Phosphatidylinositol Interactions of C-Reactive Protein and Serum Amyloid P Component with Interleukin-8 and Their Role in Regulation of Neutrophil Functions Binding of human serum amyloid P component to L-selectin Serum amyloid P inhibits granulocyte adhesion Protective effect of human serum amyloid P on CCl4-induced acute liver injury in mice. International journal of molecular medicine Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial Amyloid P Is a Sialylated Glycoprotein Inhibitor of Influenza A Viruses Serum amyloid P component binds to influenza A virus haemagglutinin and inhibits the virus infection in vitro Serum amyloid P component inhibits influenza A virus infections: in vitro and in vivo studies Extraordinary GU-rich single-strand RNA identified from SARS coronavirus contributes an excessive innate immune response. Microbes and infection Nucleic acid-sensing TLRs: trafficking and regulation Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8 Pivotal Advance: Th-1 cytokines inhibit, and Th-2 cytokines promote fibrocyte differentiation Performing Bronchoalveolar Lavage in the Mouse. Current protocols in mouse biology Mouse models of bleomycin-induced pulmonary fibrosis. Current protocols in pharmacology Sialidase inhibitors attenuate pulmonary fibrosis in a mouse model The kinetics of interaction between lymphocytes and magnetic polymer particles Dipeptidyl Peptidase IV Is a Human and Murine Neutrophil Chemorepellent Fibroblasts secrete Slit2 to inhibit fibrocyte differentiation and fibrosis Attenuated pulmonary fibrosis in sialidase-3 knockout (Neu3(-/-)) mice. American journal of physiology Lung cellular and molecular physiology Blood collection. Current protocols in neuroscience Blood sample collection in small laboratory animals Persistent Lung Inflammation and Fibrosis in Serum Amyloid P Component (Apcs-/-) Knockout Mice Developmental origin of lung macrophage diversity A single-cell atlas of the peripheral immune response in patients with severe COVID-19 Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients Severe COVID-19 is marked by a dysregulated myeloid cell compartment The Innate Immune System: Fighting on the Front Lines or Fanning the Flames of COVID-19? Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages COVID-19 severity associates with pulmonary redistribution of CD1c+ DC and inflammatory transitional and nonclassical monocytes. The Journal of Clinical Investigation. 2020. 75. Vannella KM, Wynn TA. Mechanisms of Organ Injury and Repair by Macrophages. Annual review of physiology Cell Origin Dictates Programming of Resident versus Recruited Macrophages during Acute Lung Injury. American journal of respiratory cell and molecular biology Monocyte-derived alveolar macrophages drive lung fibrosis and persist in the lung over the life span Innate Lymphoid Cells: 10 Years On Innate Lymphoid Cells of the Lung. Annual review of physiology Metabolic Control of Innate Lymphoid Cell Migration Characterization of the Inflammatory Response to Severe COVID-19 Illness Clinical and immunological features of severe and moderate coronavirus disease 2019 Novel Role for Interleukin-17 in Enhancing Type 1 Helper T Cell Immunity in the Female Genital Tract following Mucosal Herpes Simplex Virus 2 Vaccination Sex differences in IL-17 contribute to chronicity in male versus female urinary tract infection Sex-specific genetic architecture of human disease Sex Differences in Airway Remodeling in a Mouse Model of Chronic Obstructive Pulmonary Disease Sex Differences in Chronic Obstructive Pulmonary Disease Mechanisms SAP treated mice are resistant to a decline in body weight after ORN06 aspiration. Percent change in body weight for (A) both males and females, (B) males, and (C) females after the indicated treatments. Values are mean ± SEM, n = 6 (3 males and 3 females) except for PBSaspirated and then PBS-treated, where n=8 (3 males and 5 females) Organ weights as percent of total body weight at day 3 of (A) both male and female mice, (B) males, and (C) females after the indicated treatments. Values are mean ± SEM, n = 6 (3 males and 3 females) except for control Specific cell types in male and female mouse BAL. The data from Figure 2 was separated for (A) CD3 positively stained cells, (B) CD11b positively stained cells CD45 positively stained cells, and (E) Ly6G positively stained cells from male (M) and female (F) mice from each group. Values are mean ± SEM 001, and **** p < 0.0001 (1-way ANOVA, Bonferroni's test) Specific cell types in male and female mouse post-BAL lung cryosections. The data from Figure 3 was separated for (A) CD11b positively stained cells, (B) CD11c positively stained cells The data from Figures 5 D, E and F were separated for (A) alveolar wall thickness, (B) percent of alveoli with intra-alveolar exudates, and (C) percent of alveolar airspace area B -C), where n = 4. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 (1-way ANOVA, Bonferroni's test were separated for serum (A) IL-1β, (B) IL-6 (C) IL-12p70, (D) IL-23, and (E) IL-27 levels from male (M) and female (F) mice from each group. Values are mean ± SEM. For male mice and female mice n = 3 in each group Cytokine levels from male and female mice sera. The data from Supplementary figure 9 were separated for serum (A) IL-1α, (B) IL-10 (C) IL-17 MCP-1, and (H) TNF-α levels from male (M) and female (F) mice from each group